Initial List Of US Essential Medicines Focuses On Acute Care
Executive Summary
US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.
You may also be interested in...
OTC Monograph Purity Concern Among Problems Noted In US FDA FY21 Drug Quality Review
Manufacturing sites drew high marks in FY21, especially for essential medicines and complex drugs. But inspection resumption means more recalls are coming, and inspection protocols indicate problems with investigations. Meanwhile, site data suggest post-pandemic supply chain is growing even more dispersed, particularly for essential medicines, despite government onshoring initiatives.
A Few Clouds In Sunny US FDA Review Of FY21 Drug Quality: Recalls, Investigations, Offshoring
Manufacturing sites drew high marks in FY21, especially for essential medicines and complex drugs. But inspection resumption means more recalls are coming, and inspection protocols indicate problems with investigations. Meanwhile, site data suggest post-pandemic supply chain is growing even more dispersed, particularly for essential medicines, despite government onshoring initiatives.
Public-Private Consortium To Strengthen Essential Medicines Supply Under White House Initiative
President Biden’s 100-day plan relies on Defense Production Act authorities to increase resilience of critical domestic pharmaceutical supplies.